AI-powered pain assessment tool PainChek has reported sustained market growth and a 400 per cent expansion of its team just two years after its UK launch.
Over 8,500 beds in UK care homes now use PainChek technology. Globally, PainChek has facilitated over 1,300,000 pain assessments and has been contracted for over 126,000 beds across 1,500 facilities.
A secure medical device for use on mobile phones and tablets, PainChek uses AI (facial detection and analysis technology) and smart automation to detect and score pain in real time. It is the only regulatory-cleared pain assessment technology for mobile devices for care homes and has regulatory clearance as a medical device in the UK, Australia, Canada, the EU, and New Zealand.
Tandeep Gill, senior business development manager at PainChek, said: “Through government-funded pilots, integrations with eMAR and care planning partners, and a vision to move into new markets, our growth strategy is very much on track.
“Our ongoing expansion in the UK is a core part of PainChek’s plans for this year. We have recorded a surge in interest, enquiries, and uptake of PainChek from a range of care providers, from those with well-established digital systems as well as those looking to make the first entry into their digital journey. Indeed, with the UK government’s digitisation target front of mind, many care providers are realising the value, time, and cost savings digital tools can bring.
“Worldwide, cases of people living with dementia are predicted to treble to 153 million by 2050. Timely detection and management of pain is integral to ensuring high quality care and quality of life for care home residents living with dementia, and this starts with accurate pain assessment for those unable to self-report their pain.”
